

Oncology Today with Dr Neil Love: Key Presentations on Multiple Myeloma from ASH 2021

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following results was NOT reported at ASH 2021 from the Phase III CASSIOPEIA trial of patients with newly diagnosed multiple myeloma treated with bortezomib, thalidomide and dexamethasone (VTd) with or without daratumumab (dara)?
 - a. The 2-year minimum residual disease negativity rate was significantly higher with dara-VTd
 - b. Median progression-free survival was significantly higher with dara-VTd
 - c. Overall response rate was significantly higher with dara-VTd
2. Which of the following best describes the mechanism of action of the drug selinexor?
 - a. Inhibits autophagy
 - b. Inhibits DNA transcription
 - c. Inhibits homologous recombination
 - d. Inhibits nuclear export
3. In the analysis of the final overall survival results from the Phase III BELLINI trial of venetoclax (ven) in combination with bortezomib/dexamethasone (Vd) versus Vd alone, which of the following patient populations had the greatest benefit in median progression-free survival and overall survival with venVd?
 - a. Patients with t(11;14)
 - b. Patients with Bcl-2^{high}
 - c. Patients with non-t(11;14), Bcl-2^{low}
 - d. Patients with t(11;14), Bcl-2^{high}
4. Which of the following anti-BCMA (B-cell maturation antigen) CAR (chimeric antigen receptor) T-cell therapies was associated with the highest objective response rate and complete response rate in data reported at ASH 2021?
 - a. BCMA-101
 - b. Cilta-cel
 - c. CT053
 - d. Ide-cel
 - e. Bb21217
5. Which of the following is a molecular target of the novel bispecific antibody talquetamab?
 - a. BCMA
 - b. GPRC5D
 - c. FcRH5